Belgium· BE-AMP-SAM539635-00
Emgality 120 mg
A galcanezumab product containing galcanezumab, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Galcanezumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD02 (galcanezumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Galcanezumab · ATC N02CD02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Galcanezumab
- Manufacturer
- Eli Lilly Nederland
- Country
- Belgium (BE)
- ATC code
- N02CD02
- ATC class
- Galcanezumab
- Defined daily dose
- 4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb3967387EUR 431.2
- be_apb7730815
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Galcanezumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMGALITYEli Lilly Nederland B.V., Utrecht
- IcelandEmgalityEli Lilly Nederland B.V.*
- NorwayEmgalityAbacus Medicine A/S
- SpainEMGALITY 120 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAEli Lilly Nederland B.V.
- SwedenEmgality 120 mg Injektionsvätska, lösning i förfylld injektionspennaEli Lilly Nederland B.V.
- United KingdomEmgality 120mg/1ml solution for injection pre-filled pensOrganon Pharma (UK) Ltd
- SwitzerlandEmgality 120 mg, solution injectable en stylo prérempliEli Lilly (Suisse) SA
- PolandEmgalityEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emgality
- Liechtenstein · Emgality
- Norway · Emgality
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe53d989-573c-4a1f-b9df-d85f8fa99d88 GET /v1/drugs/fe53d989-573c-4a1f-b9df-d85f8fa99d88?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Emgality 120 mg",
"name_fr": "Emgality 120 mg",
"name_nl": "Emgality 120 mg",
"amp_code": "SAM539635-00",
"strengths": [
"120.0000",
"120.0000"
],
"pack_count": 3,
"substances": [
"Galcanezumab",
"Sodium Chloride",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Galcanezumab",
"authorisation_numbers": [
"EU/1/18/1330/002",
"EU/1/18/1330/005",
"EU/1/18/1330/001"
]
}See everything about galcanezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.